Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
... according to advfn. So the market seems to like it?
LSE seems to be having an issue with all its data ATM?
...a bunch of new/dormant posters start appearing this morning trying to twist the narrative of a results RNS by applying their 'interpretation' of the RNS.
I feel like this is a recurring pattern too.
I like DC's description of potential bulletin board de-rampers... tyre kickers:
"29/10/2023
10:09 dominiccummings: #6707 Tyre kicker - wondering if he can create a panic. Ignore him (or her) the appropriate authorities or the auditors will sort their problem."
@dragon101, thanks, I genuinely don't know how it works RE audit deadlines, a fine for the auditors sounds much more feasible though. I probably should be doing my own research into this though.
"The Company's auditor, BDO LLP, has requested additional time to complete their standard audit due to unforeseen circumstances impacting the audit engagement team. Scancell's Board has been advised that the audit is substantially complete and has not been advised of any material audit issues."
'Substantially complete' at least? Cutting it fine either way.
Don't fully understand audits but the implication is if not in by Tues close it's share suspension? As the poster says though 'Underlying reason is not material according to latest RNS' so no fault on Scancells side.
As per that posters comment and somewhere else I read it sounds like a potentially good trading opportunity to buy before a potential suspension and wait for it to re-open?
Indeed.
60 + staff and still need extra hands on deck for processing the trial samples. Encouraging IMO.
Ah I didn't see ICB888's post, their explanation says what I meant to say better.
Let's not forget the Genmab deal was done way before the idea of Scancell even having a Chief Business Officer. So clearly they was enough nous in the company previously to get deals of some kind done.
IMO Dr Semhi is a perhaps a big deal closer/finaliser?
"Dragon....personally...whatever it takes to get the SP elevated !"
This! Couldn't care less what the reason is. An unsubstantiated buyout rumour will do me.
Regarding Nasdaq listing, I don't think anyone replied to my question about the implications for us shareholders shirt, medium and long term?
Worth a read IMO:
https://investor.seagen.com/press-releases/news-details/2022/Seagen-Astellas-and-Merck-Announce-Results-of-Clinical-Trial-Investigating-PADCEV-enfortumab-vedotin-ejfv-with-KEYTRUDA-pembrolizumab-and-PADCEV-as-Monotherapy-in-First-Line-Advanced-Urothelial-Cancer/default.aspx
https://www.fiercepharma.com/pharma/esmo-seagen-astellas-and-merck-knock-it-out-park-padcev-keytruda-combo-bladder-cancer
https://www.oncologypipeline.com/apexonco/esmo-2023-daiichi-shows-why-merck-paid-2bn-cdh6
Top analysis as ever JB1.
Assuming this were to happen what are the potential short,medium and long term implications for shareholders?
Looks like it was published yesterday TF:
https://jitc.bmj.com/content/11/10/e006966.info
...taken advantage of the (second) overreaction to the second auditor delay with a 150k buy.
"....BDO has form on this...and more than once..."
Time for a new auditor I seems.
Not too unhappy though as I, and by the looks of it others, have used it as a cheeky top up opportunity.
To be fair you can't argue with the clarity of the RNS, stating exactly what is going on, Scancell in the past would have no doubt been vague about which would have caused uncertainty. Scancell have seen to have improved noticeably in this department.
TF Dr Semhi is a she.
I guess we agree to disagree Bojo.
Your argument falls over for me somewhat because of all the numerous pre-clinal/early phase deals that happen all the time. IMO.